# aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/ATYR/atyr-pharma-to-present-at-the-leerink-partners-global-healthcare-conference
Ticker: ATYR
Company: aTyr Pharma
Source: aTyr Pharma
Published: 2026-02-18 13:00 EST
Original Source URL: https://investors.atyrpharma.com
## Summary

SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.

## Article Body
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S.
## Recent Company News
- 2026-05-15 12:00 EST — [aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-first-quarter-2026-results-and-provides-corporate-update) — Source: aTyr Pharma
- 2026-05-13 20:01 EST — [aTyr Pharma to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ATYR/atyr-pharma-to-participate-in-upcoming-investor-conferences) — Source: aTyr Pharma
- 2026-05-11 20:01 EST — [aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting](https://biopharmsignal.com/news/ATYR/atyr-pharma-provides-regulatory-and-clinical-update-for-efzofitimod-in-pulmonary-sarcoidosis-following-fda-type-c-meeting) — Source: aTyr Pharma
- 2026-03-05 21:01 EST — [aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-fourth-quarter-and-full-year-2025-results-and-provides-corporate-update) — Source: aTyr Pharma
- 2026-02-20 21:01 EST — [aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ATYR/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: aTyr Pharma
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)